Replies to post #146924 on Biotech Values

[BTH]

Because 011 is highly specific to a certain subset of breast cancer, like TDM1, and would be complementary in Roche's portfolio, not a competitor.

[jq1234]

Because they maximize the potential of the drug if the drug works. That is what you want to have in a partner.

Roche and NVS 's BC and Roche's Melanoma are for subsets of cancers, and certain stages of cancer, they don't overlap with 011 target that much. It would complement not compete against their drugs.

Those without much oncology experiences won't develop the drug to its potential. Look at ARRY MEK Selumetinib licensed to AZN. The drug is active, but still in ph2 after 8 years. Similarly active MEK inhibitor GSK licensed just 3 years ago already filed NDA in BRAF melanoma, and in ph3 combination with BRAF inhibitor for BRAF melanoma leaping in front of even Roche who has the first drug approved for BRAF melanoma.

Development plan and execution matter a great deal in oncology especially for target therapy as both single and combination therapy. Those come from experiences.